Overview

GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to analyze and compare the efficacy, the response rate, the CR and the response rate duration of both induction treatments and both maintenance treatments
Phase:
Phase 3
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
Bortezomib
Melphalan
Prednisone
Thalidomide